eVOLVE-Lung02: A phase 3 study of first-line (1L) volrustomig plus chemotherapy (CT) versus pembrolizumab plus CT in metastatic non-small-cell lung cancer (mNSCLC) with PD-L1 tumor cell (TC) expression <50%.

Authors

Melissa Lynne Johnson

Sarah Cannon Research Institute, Nashville, TN

Melissa Lynne Johnson , Edurne Arriola , Terufumi Kato , Nicolas Girard , Shirish M. Gadgeel , Jie Wang , Xia Li , Caitlin Lowery , Lee M. Krug , Myung-Ju Ahn

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Treatment patterns and unmet need for patients with advanced non-small cell lung cancer and poor performance status: A real-world evidence study.

First Author: Stephen V. Liu

insert_chart_outlined

Poster

2018 ASCO-SITC Clinical Immuno-Oncology Symposium

bookmark_border

Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations.

First Author: Laurent Mhanna

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

A phase III, randomized, open-label trial of nivolumab (anti-PD-1; BMS-936558, ONO-4538) versus investigator's choice chemotherapy (ICC) as first-line therapy for stage IV or recurrent PD-L1+ non-small cell lung cancer (NSCLC).

First Author: David Paul Carbone

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Real-world outcomes of first-line immune checkpoint inhibitors with or without chemotherapy in KRAS G12C altered NSCLC according to PD-L1 status.

First Author: Charu Aggarwal